Pfizer’s (PFE) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Pfizer (NYSE:PFE) in a research note published on Monday morning, Benzinga reports. The firm currently has a $45.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also recently issued reports on PFE. Argus cut Pfizer from a buy rating to a hold rating in a research note on Friday, March 22nd. TD Cowen lowered Pfizer from an outperform rating to a market perform rating and set a $32.00 price target on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim initiated coverage on Pfizer in a research report on Friday, February 23rd. They issued a buy rating and a $36.00 price objective for the company. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average price target of $36.88.

Pfizer Stock Performance

NYSE:PFE opened at $25.90 on Monday. Pfizer has a 1-year low of $25.61 and a 1-year high of $41.33. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The business has a 50 day moving average of $27.27 and a 200 day moving average of $28.84. The company has a market capitalization of $146.66 billion, a price-to-earnings ratio of 71.94, a PEG ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the previous year, the business posted $1.14 EPS. The business’s quarterly revenue was down 41.3% on a year-over-year basis. On average, sell-side analysts predict that Pfizer will post 2.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently modified their holdings of PFE. Cardinal Capital Management boosted its position in Pfizer by 13.9% during the 1st quarter. Cardinal Capital Management now owns 88,811 shares of the biopharmaceutical company’s stock valued at $2,465,000 after acquiring an additional 10,863 shares in the last quarter. Viking Fund Management LLC grew its stake in Pfizer by 27.7% in the first quarter. Viking Fund Management LLC now owns 275,000 shares of the biopharmaceutical company’s stock worth $7,631,000 after purchasing an additional 59,700 shares during the period. Exeter Financial LLC raised its holdings in Pfizer by 75.6% in the first quarter. Exeter Financial LLC now owns 27,186 shares of the biopharmaceutical company’s stock worth $725,000 after purchasing an additional 11,704 shares in the last quarter. Sage Investment Advisers LLC increased its stake in shares of Pfizer by 15.1% in the 1st quarter. Sage Investment Advisers LLC now owns 8,447 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 1,109 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC lifted its holdings in shares of Pfizer by 149.7% during the first quarter. Wealthcare Advisory Partners LLC now owns 129,868 shares of the biopharmaceutical company’s stock valued at $3,604,000 after purchasing an additional 77,868 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.